GOLDEN, Colo. — Oct. 25, 2016 — PharmaJet today announced a collaboration with Vaccibody AS to provide needle-free injection technology for the study of a vaccine to eradicate HPV. This disease is the main cause of cervical cancer affecting 530,000 women globally annually
Read more Golden, Co. — August 30, 2016 — PharmaJet today announced a multi-year agreement with the World Health Organization to provide PharmaJet’s Needle-free technology to be used in the global effort to eradicate polio. The PharmaJet Tropis® Needle-free device has been proven to be safe, fast and easy-to-use with no possibility
Read more Golden, Co. — August 3, 2016 — PharmaJet, the maker of innovative, needle-free injection technology, announced that the National Institutes of Health will use the PharmaJet Stratis® needle-free device in a DNA vaccine clinical trial for the Zika virus. DNA vaccines are the way of the future. Unlike traditional vaccines,
Read more GOLDEN, Colo. – March 17, 2015 – PharmaJet, the maker of innovative needle-free technology, today announced survey data revealing that healthcare providers (HCPs) would recommend the needle-free injector to colleagues and believed that the use of such a device had the capacity to increase vaccination compliance.
Read more GOLDEN, Colo. – February 26, 2015– Today, PharmaJet, the maker of innovative, needle-free injector technology, announced the release of survey data demonstrating consumer satisfaction with the PharmaJet Needle-Free Injector for seasonal flu vaccinations.
Read more GOLDEN, Colo. – September 30, 2014 – A clinical study published in the August 23, 2014 issue of The Lancet demonstrated that delivery of AFLURIA® (Influenza Vaccine) with the PharmaJet Needle-Free Injector compared favorably to traditional needle and syringe delivery. The U.S. Food and Drug Administration (FDA) recently approved the
Read more KING OF PRUSSIA, Penn. / GOLDEN, Colo. – August 19, 2014 – PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet
Read more GOLDEN, Colo. – Feb. 22, 2013 – PharmaJet Inc. has entered into a collaboration agreement with CureVac GmbH for delivery of CureVac’s mRNA-based vaccine portfolio including targets in oncology and infectious diseases, using the PharmaJet needle-free jet injector platform.
Read more GOLDEN, Colo. – Feb. 20, 2013 – PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
Read more GOLDEN, Colo. ‐ Nov. 29, 2012 – PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria® influenza vaccine to be delivered with the PharmaJet Stratis® needle‐free jet injector, as soon as the 2013‐2014 flu season.
Read more GOLDEN, Colo. – March 22, 2011 – The U.S. Food and Drug Administration (FDA) has awarded PharmaJet 510(k) clearance to market a 0.1mL Intradermal (ID) Needle-free Injection System.
Read more CDC Awards Contract to PharmaJet® for Development of Needle‐Free Intradermal Vaccine Delivery Device
GOLDEN, Colo. – Jan. 27, 2011 – The Centers for Disease Control (CDC) has awarded PharmaJet with a substantial grant to develop needle-free injection devices for intradermal (ID) vaccine delivery.
Read more